Bank of New York Mellon Corp Decreases Stake in Danaher Corporation $DHR

Bank of New York Mellon Corp lessened its stake in Danaher Corporation (NYSE:DHR) by 21.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,727,655 shares of the conglomerate’s stock after selling 1,320,109 shares during the quarter. Bank of New York Mellon Corp’s holdings in Danaher were worth $1,082,255,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. JPL Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter valued at about $25,000. Elevated Capital Advisors LLC acquired a new position in Danaher during the fourth quarter worth about $26,000. WFA of San Diego LLC purchased a new stake in shares of Danaher in the second quarter valued at about $26,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Danaher in the third quarter valued at approximately $27,000. Finally, Financial Life Planners acquired a new stake in shares of Danaher in the third quarter valued at approximately $32,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 2.2%

Shares of NYSE:DHR opened at $175.97 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm has a market cap of $124.54 billion, a price-to-earnings ratio of 34.04, a PEG ratio of 2.40 and a beta of 0.81. The stock’s 50-day moving average price is $181.91 and its two-hundred day moving average price is $207.20. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the firm posted $1.88 EPS. The company’s revenue was up 3.7% on a year-over-year basis. On average, research analysts forecast that Danaher Corporation will post 8.43 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is 30.95%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DHR. UBS Group cut their price objective on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Robert W. Baird dropped their price target on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. Barclays cut their price target on Danaher from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Tuesday, April 14th. The Goldman Sachs Group decreased their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Monday, April 13th. Finally, Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday. Nineteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $238.24.

Key Stories Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher’s SCIEX unit introduced new product and software updates at ASMS, including the novus V55 system with SCIEX OS 5.0 and AI enablement tools, plus broader ZenoTOF platform expansions. These launches suggest continued innovation and support Danaher’s life sciences growth story. Article: SCIEX Launches the novus V55 System With SCIEX OS 5.0 Software and AI Enablement Tools
• Positive Sentiment: The SCIEX ZenoTOF platform updates and collaborations could improve workflow efficiency and strengthen Danaher’s competitive position in advanced analytical instruments. Article: SCIEX Advances the ZenoTOF Line With Platform-Wide Expansions in Software, Integrations, and Key Collaborations
• Neutral Sentiment: Recent commentary is focused on whether Danaher stock has become more attractive after its pullback, but the article frames this as a valuation debate rather than a clear catalyst. Article: Is It Time To Reassess Danaher (DHR) After Its Recent Share Price Weakness?
• Neutral Sentiment: A broader healthcare valuation piece highlighted large-cap healthcare stocks with expensive valuations, which may keep pressure on sentiment for Danaher if investors remain focused on multiples. Article: These 10 large-cap US healthcare companies carry the market’s most expensive valuations

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.